Adagio Therapeutics, Inc. (NASDAQ: ADGI) Stock Competitors & Peer Comparison
See ADGI's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ADGI and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ADGI | $4.64 | +0.87% | 505.7M | -1.76 | -$2.63 | N/A |
| VRTX | $479.00 | +0.34% | 121.6B | 25.45 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $667.17 | +1.70% | 68.7B | 14.62 | $45.63 | +0.54% |
| ARGX | $888.82 | -3.20% | 55.3B | 80.22 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $188.07 | -0.61% | 40B | -26.60 | -$7.07 | N/A |
| RVMDW | $9.55 | +0.53% | 39.8B | -2.27 | -$4.15 | N/A |
| ALNY | $278.40 | +2.44% | 37.2B | 50.16 | $5.55 | N/A |
| ONC | $325.90 | +0.00% | 34.8B | 72.91 | $4.47 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ADGI vs VRTX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, VRTX has a market cap of 121.6B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while VRTX trades at $479.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas VRTX's P/E ratio is 25.45. In terms of profitability, ADGI's ROE is -0.53%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ADGI is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check VRTX's competition here
Verona Pharma plc (NASDAQ: VRNA)
ADGI vs VRNA Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ADGI's ROE is -0.53%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ADGI is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check VRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ADGI vs REGN Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, REGN has a market cap of 68.7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while REGN trades at $667.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas REGN's P/E ratio is 14.62. In terms of profitability, ADGI's ROE is -0.53%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ADGI is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check REGN's competition here
argenx SE (NASDAQ: ARGX)
ADGI vs ARGX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, ARGX has a market cap of 55.3B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while ARGX trades at $888.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas ARGX's P/E ratio is 80.22. In terms of profitability, ADGI's ROE is -0.53%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, ADGI is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
ADGI vs SGEN Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ADGI's ROE is -0.53%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ADGI is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ADGI vs RVMD Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, RVMD has a market cap of 40B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while RVMD trades at $188.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas RVMD's P/E ratio is -26.60. In terms of profitability, ADGI's ROE is -0.53%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ADGI is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ADGI vs RVMDW Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, RVMDW has a market cap of 39.8B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while RVMDW trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas RVMDW's P/E ratio is -2.27. In terms of profitability, ADGI's ROE is -0.53%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, ADGI is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check RVMDW's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
ADGI vs ALNY Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, ALNY has a market cap of 37.2B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while ALNY trades at $278.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas ALNY's P/E ratio is 50.16. In terms of profitability, ADGI's ROE is -0.53%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ADGI is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check ALNY's competition here
BeOne Medicines AG (NASDAQ: ONC)
ADGI vs ONC Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, ONC has a market cap of 34.8B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while ONC trades at $325.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas ONC's P/E ratio is 72.91. In terms of profitability, ADGI's ROE is -0.53%, compared to ONC's ROE of +0.12%. Regarding short-term risk, ADGI is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check ONC's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ADGI vs ROIV Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, ROIV has a market cap of 25B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while ROIV trades at $34.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas ROIV's P/E ratio is -35.69. In terms of profitability, ADGI's ROE is -0.53%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ADGI is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
ADGI vs INCY Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, INCY has a market cap of 23.7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while INCY trades at $118.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas INCY's P/E ratio is 15.98. In terms of profitability, ADGI's ROE is -0.53%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ADGI is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
ADGI vs BNTX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, BNTX has a market cap of 23B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while BNTX trades at $91.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas BNTX's P/E ratio is -19.72. In terms of profitability, ADGI's ROE is -0.53%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ADGI is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
ADGI vs INSM Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, INSM has a market cap of 22.7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while INSM trades at $104.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas INSM's P/E ratio is -18.21. In terms of profitability, ADGI's ROE is -0.53%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ADGI is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check INSM's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ADGI vs UTHR Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, UTHR has a market cap of 22.4B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while UTHR trades at $527.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas UTHR's P/E ratio is 19.49. In terms of profitability, ADGI's ROE is -0.53%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ADGI is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
ADGI vs MRNA Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, MRNA has a market cap of 22.1B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while MRNA trades at $55.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas MRNA's P/E ratio is -6.83. In terms of profitability, ADGI's ROE is -0.53%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, ADGI is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check MRNA's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ADGI vs BGNE Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ADGI's ROE is -0.53%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ADGI is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ADGI vs DNA-WT Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ADGI's ROE is -0.53%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ADGI is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check DNA-WT's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ADGI vs NBIX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, NBIX has a market cap of 17.7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while NBIX trades at $176.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas NBIX's P/E ratio is 25.49. In terms of profitability, ADGI's ROE is -0.53%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, ADGI is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check NBIX's competition here
Genmab A/S (NASDAQ: GMAB)
ADGI vs GMAB Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while GMAB trades at $28.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas GMAB's P/E ratio is 20.72. In terms of profitability, ADGI's ROE is -0.53%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, ADGI is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check GMAB's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ADGI vs BBIO Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, BBIO has a market cap of 16.5B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while BBIO trades at $84.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas BBIO's P/E ratio is -22.49. In terms of profitability, ADGI's ROE is -0.53%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ADGI is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check BBIO's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ADGI vs JAZZ Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, JAZZ has a market cap of 16B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while JAZZ trades at $255.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas JAZZ's P/E ratio is 19.86. In terms of profitability, ADGI's ROE is -0.53%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ADGI is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check JAZZ's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ADGI vs ASND Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, ASND has a market cap of 15.7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while ASND trades at $253.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas ASND's P/E ratio is -104.72. In terms of profitability, ADGI's ROE is -0.53%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ADGI is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ADGI vs EXEL Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, EXEL has a market cap of 14B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while EXEL trades at $55.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas EXEL's P/E ratio is 16.71. In terms of profitability, ADGI's ROE is -0.53%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ADGI is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check EXEL's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ADGI vs MDGL Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, MDGL has a market cap of 12.7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while MDGL trades at $551.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas MDGL's P/E ratio is -43.07. In terms of profitability, ADGI's ROE is -0.53%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, ADGI is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check MDGL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ADGI vs KRTX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ADGI's ROE is -0.53%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ADGI is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check KRTX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ADGI vs AXSM Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, AXSM has a market cap of 12.3B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while AXSM trades at $238.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas AXSM's P/E ratio is -62.24. In terms of profitability, ADGI's ROE is -0.53%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ADGI is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check AXSM's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ADGI vs ARWR Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, ARWR has a market cap of 12B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while ARWR trades at $85.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas ARWR's P/E ratio is -39.78. In terms of profitability, ADGI's ROE is -0.53%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ADGI is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ADGI vs BMRN Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while BMRN trades at $60.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas BMRN's P/E ratio is 28.98. In terms of profitability, ADGI's ROE is -0.53%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ADGI is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check BMRN's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ADGI vs RNAM Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ADGI's ROE is -0.53%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ADGI is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check RNAM's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ADGI vs TECH Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while TECH trades at $71.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas TECH's P/E ratio is 36.91. In terms of profitability, ADGI's ROE is -0.53%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ADGI is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check TECH's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ADGI vs KRYS Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, KRYS has a market cap of 10.4B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while KRYS trades at $351.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas KRYS's P/E ratio is 47.03. In terms of profitability, ADGI's ROE is -0.53%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ADGI is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check KRYS's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ADGI vs SMMT Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, SMMT has a market cap of 10.2B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while SMMT trades at $13.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas SMMT's P/E ratio is -8.19. In terms of profitability, ADGI's ROE is -0.53%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ADGI is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ADGI.Check SMMT's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ADGI vs CYTK Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, CYTK has a market cap of 10B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while CYTK trades at $80.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas CYTK's P/E ratio is -13.83. In terms of profitability, ADGI's ROE is -0.53%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ADGI is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check CYTK's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ADGI vs HALO Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, HALO has a market cap of 9.7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while HALO trades at $81.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas HALO's P/E ratio is 17.64. In terms of profitability, ADGI's ROE is -0.53%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ADGI is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check HALO's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ADGI vs RXDX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ADGI's ROE is -0.53%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ADGI is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
ADGI vs ABVX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, ABVX has a market cap of 9.4B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while ABVX trades at $128.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas ABVX's P/E ratio is -67.09. In terms of profitability, ADGI's ROE is -0.53%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ADGI is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check ABVX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ADGI vs IONS Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, IONS has a market cap of 9.2B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while IONS trades at $55.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas IONS's P/E ratio is -32.53. In terms of profitability, ADGI's ROE is -0.53%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ADGI is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check IONS's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ADGI vs NUVL Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ADGI's ROE is -0.53%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ADGI is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check NUVL's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ADGI vs KYMR Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while KYMR trades at $110.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas KYMR's P/E ratio is -31.18. In terms of profitability, ADGI's ROE is -0.53%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ADGI is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check KYMR's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ADGI vs CRNX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while CRNX trades at $83.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas CRNX's P/E ratio is -16.35. In terms of profitability, ADGI's ROE is -0.53%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ADGI is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check CRNX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ADGI vs PRAX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, PRAX has a market cap of 8.8B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while PRAX trades at $315.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas PRAX's P/E ratio is -23.62. In terms of profitability, ADGI's ROE is -0.53%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ADGI is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check PRAX's competition here
Alkermes plc (NASDAQ: ALKS)
ADGI vs ALKS Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, ALKS has a market cap of 8.8B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while ALKS trades at $52.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas ALKS's P/E ratio is 55.51. In terms of profitability, ADGI's ROE is -0.53%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, ADGI is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check ALKS's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ADGI vs IMGN Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ADGI's ROE is -0.53%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ADGI is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check IMGN's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ADGI vs PTGX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, PTGX has a market cap of 8.7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while PTGX trades at $135.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas PTGX's P/E ratio is -74.90. In terms of profitability, ADGI's ROE is -0.53%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ADGI is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check PTGX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ADGI vs SYRE Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, SYRE has a market cap of 8.7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while SYRE trades at $100.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas SYRE's P/E ratio is -48.10. In terms of profitability, ADGI's ROE is -0.53%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ADGI is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check SYRE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ADGI vs TGTX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, TGTX has a market cap of 8.5B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while TGTX trades at $55.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas TGTX's P/E ratio is 19.16. In terms of profitability, ADGI's ROE is -0.53%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ADGI is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check TGTX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ADGI vs BPMC Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ADGI's ROE is -0.53%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ADGI is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ADGI vs APGE Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while APGE trades at $134.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas APGE's P/E ratio is -31.01. In terms of profitability, ADGI's ROE is -0.53%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ADGI is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check APGE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ADGI vs IMVT Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, IMVT has a market cap of 8.2B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while IMVT trades at $40.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas IMVT's P/E ratio is -15.01. In terms of profitability, ADGI's ROE is -0.53%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ADGI is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check IMVT's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ADGI vs CERE Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas CERE's P/E ratio is -16.47. In terms of profitability, ADGI's ROE is -0.53%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ADGI is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check CERE's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ADGI vs PCVX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, PCVX has a market cap of 8B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while PCVX trades at $55.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas PCVX's P/E ratio is -8.07. In terms of profitability, ADGI's ROE is -0.53%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ADGI is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check PCVX's competition here
Metsera, Inc. (NASDAQ: MTSR)
ADGI vs MTSR Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ADGI's ROE is -0.53%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ADGI is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check MTSR's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ADGI vs IBRX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, IBRX has a market cap of 7.3B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while IBRX trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas IBRX's P/E ratio is -8.22. In terms of profitability, ADGI's ROE is -0.53%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ADGI is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check IBRX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ADGI vs RYTM Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, RYTM has a market cap of 7.3B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while RYTM trades at $106.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas RYTM's P/E ratio is -33.91. In terms of profitability, ADGI's ROE is -0.53%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ADGI is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check RYTM's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ADGI vs MIRM Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, MIRM has a market cap of 7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while MIRM trades at $114.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas MIRM's P/E ratio is -8.39. In terms of profitability, ADGI's ROE is -0.53%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ADGI is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check MIRM's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ADGI vs COGT Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, COGT has a market cap of 6.9B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while COGT trades at $40.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas COGT's P/E ratio is -19.17. In terms of profitability, ADGI's ROE is -0.53%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ADGI is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check COGT's competition here
Merus N.V. (NASDAQ: MRUS)
ADGI vs MRUS Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ADGI's ROE is -0.53%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ADGI is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ADGI vs ACLX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ADGI's ROE is -0.53%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ADGI is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ADGI vs RETA Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas RETA's P/E ratio is -66.29. In terms of profitability, ADGI's ROE is -0.53%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ADGI is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check RETA's competition here
Erasca, Inc. (NASDAQ: ERAS)
ADGI vs ERAS Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, ERAS has a market cap of 6.6B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while ERAS trades at $18.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas ERAS's P/E ratio is -20.29. In terms of profitability, ADGI's ROE is -0.53%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ADGI is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
ADGI vs CGON Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, CGON has a market cap of 6.5B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while CGON trades at $73.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas CGON's P/E ratio is -31.55. In terms of profitability, ADGI's ROE is -0.53%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ADGI is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check CGON's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
ADGI vs XENE Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, XENE has a market cap of 6.4B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while XENE trades at $65.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas XENE's P/E ratio is -14.00. In terms of profitability, ADGI's ROE is -0.53%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ADGI is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check XENE's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ADGI vs BLTE Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while BLTE trades at $158.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas BLTE's P/E ratio is -84.72. In terms of profitability, ADGI's ROE is -0.53%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, ADGI is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check BLTE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ADGI vs PTCT Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, PTCT has a market cap of 6.3B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while PTCT trades at $75.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas PTCT's P/E ratio is -32.53. In terms of profitability, ADGI's ROE is -0.53%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, ADGI is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check PTCT's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ADGI vs CNTA Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ADGI's ROE is -0.53%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ADGI is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ADGI vs LGND Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, LGND has a market cap of 6B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while LGND trades at $297.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas LGND's P/E ratio is 35.67. In terms of profitability, ADGI's ROE is -0.53%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ADGI is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ADGI vs SRRK Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, SRRK has a market cap of 5.9B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while SRRK trades at $48.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas SRRK's P/E ratio is -13.63. In terms of profitability, ADGI's ROE is -0.53%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ADGI is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ADGI vs CDTX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ADGI's ROE is -0.53%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ADGI is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
ADGI vs ABCM Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ADGI's ROE is -0.53%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ADGI is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ADGI vs ISEE Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ADGI's ROE is -0.53%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ADGI is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check ISEE's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ADGI vs TVTX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while TVTX trades at $56.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas TVTX's P/E ratio is -257.64. In terms of profitability, ADGI's ROE is -0.53%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ADGI is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check TVTX's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ADGI vs APLS Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas APLS's P/E ratio is 38.35. In terms of profitability, ADGI's ROE is -0.53%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ADGI is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check APLS's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ADGI vs TERN Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas TERN's P/E ratio is -51.41. In terms of profitability, ADGI's ROE is -0.53%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ADGI is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ADGI vs DFTX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while DFTX trades at $42.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas DFTX's P/E ratio is N/A. In terms of profitability, ADGI's ROE is -0.53%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, ADGI is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for ADGI.Check DFTX's competition here
Veradermics, Incorporated (NYSE: MANE)
ADGI vs MANE Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while MANE trades at $111.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas MANE's P/E ratio is -35.45. In terms of profitability, ADGI's ROE is -0.53%, compared to MANE's ROE of -0.84%. Regarding short-term risk, ADGI is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check MANE's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ADGI vs FOLD Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ADGI's ROE is -0.53%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ADGI is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check FOLD's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ADGI vs CRSP Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, CRSP has a market cap of 4.5B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while CRSP trades at $46.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas CRSP's P/E ratio is -9.15. In terms of profitability, ADGI's ROE is -0.53%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ADGI is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check CRSP's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ADGI vs AKRO Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ADGI's ROE is -0.53%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ADGI is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check AKRO's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ADGI vs EWTX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, EWTX has a market cap of 4.5B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while EWTX trades at $41.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas EWTX's P/E ratio is -25.06. In terms of profitability, ADGI's ROE is -0.53%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ADGI is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check EWTX's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ADGI vs ALPN Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ADGI's ROE is -0.53%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ADGI is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check ALPN's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ADGI vs CAI Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while CAI trades at $15.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas CAI's P/E ratio is -85.97. In terms of profitability, ADGI's ROE is -0.53%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ADGI is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check CAI's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ADGI vs DNTH Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, DNTH has a market cap of 4.4B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while DNTH trades at $104.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas DNTH's P/E ratio is -25.30. In terms of profitability, ADGI's ROE is -0.53%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ADGI is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check DNTH's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
ADGI vs ACAD Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while ACAD trades at $25.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas ACAD's P/E ratio is 12.45. In terms of profitability, ADGI's ROE is -0.53%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ADGI is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
ADGI vs DYN Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, DYN has a market cap of 4.2B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while DYN trades at $25.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas DYN's P/E ratio is -7.96. In terms of profitability, ADGI's ROE is -0.53%, compared to DYN's ROE of -0.58%. Regarding short-term risk, ADGI is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check DYN's competition here
Opthea Limited (NASDAQ: OPT)
ADGI vs OPT Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas OPT's P/E ratio is -1.52. In terms of profitability, ADGI's ROE is -0.53%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ADGI is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check OPT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ADGI vs MRTX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ADGI's ROE is -0.53%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ADGI is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check MRTX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
ADGI vs VKTX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while VKTX trades at $34.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas VKTX's P/E ratio is -8.42. In terms of profitability, ADGI's ROE is -0.53%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, ADGI is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check VKTX's competition here
Celcuity Inc. (NASDAQ: CELC)
ADGI vs CELC Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, CELC has a market cap of 4B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while CELC trades at $82.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas CELC's P/E ratio is -21.09. In terms of profitability, ADGI's ROE is -0.53%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ADGI is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check CELC's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
ADGI vs CPRX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ADGI's ROE is -0.53%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ADGI is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check CPRX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
ADGI vs ELVN Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while ELVN trades at $52.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas ELVN's P/E ratio is -31.58. In terms of profitability, ADGI's ROE is -0.53%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, ADGI is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check ELVN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
ADGI vs RYZB Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ADGI's ROE is -0.53%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ADGI is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check RYZB's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
ADGI vs DNLI Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while DNLI trades at $23.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas DNLI's P/E ratio is -8.18. In terms of profitability, ADGI's ROE is -0.53%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ADGI is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check DNLI's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
ADGI vs CBAY Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ADGI's ROE is -0.53%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ADGI is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check CBAY's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW)
ADGI vs NAMSW Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, NAMSW has a market cap of 3.6B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while NAMSW trades at $19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas NAMSW's P/E ratio is -10.75. In terms of profitability, ADGI's ROE is -0.53%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, ADGI is more volatile compared to NAMSW. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check NAMSW's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
ADGI vs ADPT Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while ADPT trades at $22.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas ADPT's P/E ratio is -41.74. In terms of profitability, ADGI's ROE is -0.53%, compared to ADPT's ROE of -0.24%. Regarding short-term risk, ADGI is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check ADPT's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
ADGI vs LEGN Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, LEGN has a market cap of 3.6B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while LEGN trades at $19.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas LEGN's P/E ratio is -28.34. In terms of profitability, ADGI's ROE is -0.53%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, ADGI is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for ADGI.Check LEGN's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
ADGI vs SWTX Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ADGI's ROE is -0.53%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, ADGI is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check SWTX's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS)
ADGI vs NAMS Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, NAMS has a market cap of 3.5B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while NAMS trades at $30.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas NAMS's P/E ratio is -19.01. In terms of profitability, ADGI's ROE is -0.53%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, ADGI is more volatile compared to NAMS. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check NAMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
ADGI vs RCUS Comparison July 2026
Adagio Therapeutics, Inc. (NASDAQ: ADGI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADGI stands at 505.7M. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, ADGI is priced at $4.64 on the NASDAQ, while RCUS trades at $27.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADGI currently has a P/E ratio of -1.76, whereas RCUS's P/E ratio is -8.56. In terms of profitability, ADGI's ROE is -0.53%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, ADGI is more volatile compared to RCUS. This indicates higher risk in terms of short-term price fluctuations for ADGI.Check RCUS's competition here